Abstract 12P
Background
Despite enough evidence supporting equal outcomes of Breast Conservation Therapy (BCT) and Modified Radical Mastectomy (MRM) in early breast, rates of mastectomy are still high in most of the regions of India barring few metro cities. Other than clinical parameters and availability of resources, several other sociodemographic factors and personal beliefs play a very vital role in decision making about type of surgery by Indian patients. This study aimed to investigate the factors which influenced the surgical choice in patients eligible for BCS.
Methods
Of 316 women who underwent surgery for Ca Breast in our department between Jan 2020 -Dec 2021, 119 were found to be eligible for BCS. A questionnaire containing details of various sociodemographic factors, individual beliefs and role of others in decision making was filled by patients. Univariate analysis was employed to determine the factors associated with the different surgical choices.
Results
Among 119 patients eligible for BCS; 12 patients were excluded for lack of consent or contact. Of 107 patients, 25 chose BCS and 82 chose MRM. On analysis of various socio-demographic factors, education above primary school, higher income, and urban residence was found to be significantly associated (P<0.02, P<0.03, P<0.02 respectively) with choice of BCS. Patients who received NACT or had family history of any malignancy were more inclined towards MRM, though the difference did not reach statistical significance. Among patients who chose MRM, about 2/3 feared about cancer recurrence or possibility of tumour being left behind with more conservative surgery while only 5% took this decision to avoid radiotherapy. Patient’s desire to hide their disease and surgery status as well as surgeons reassurance of equivalent survival were the driving factors among patients who chose BCS.
Conclusions
Decision making for type of surgery among breast cancer patients is complicated & governed by fears, social pressures, financial concerns & cosmetic expectations, which are slightly different among Indian women as compared to the western world. A better understanding of these may help increase the rate of BCS in rural and suburban population of India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
19P - Cardiac and lung sparing radiotherapy in breast and chest wall irradiation with surface guided radiotherapy using deep inspiratory breath hold technique
Presenter: Ravi Shankar Bellala
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01